Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Dialysis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Dialysis
    Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention - (JAMA)
    TopAbstracts in Dialysis 12/08/2009 - (DGNews)
    Many Dialysis Patients Undergoing PCI Receive Improper Medication, With Increased Risk of Bleeding - (DGNews)
    Model Predicts Dialysis Patients' Likelihood of Survival - (DGNews)
    TopAbstracts in Dialysis 11/24/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Dialysis
    • The State of the Science in Managing Systemic Lupus Erythematosus: Update From EULAR 2008
    • Understanding Current and Emerging Treatments for Systemic Lupus Erythematosus
    • Evaluating New Treatment Strategies for Lupus Nephritis
    • Can Treatments for Disordered Mineral Metabolism Reduce Adverse Outcomes in CKD?
    • Cardiovascular Actions of Vitamin D: What Can We Learn from Dialysis Study?

      Webcasts/CME archive

       Recent cases - Dialysis
        Intramural Duodenal Hematoma And Hemoperitoneum After Endoscopic Treatment In A Patient With Chronic Renal Failure On Hemodialysis: A Case Report
        Infective Endocarditis Caused by Salmonella Enteritidis in a Dialysis Patient: A Case Report and Literature Review
        Catheter-related Bacteremia Caused by Agrobacterium radiobacter in a Hemodialysis Patient
        Pregnancy in End-Stage Renal Disease Patients on Hemodialysis: Two Case Reports
        A 44 Year-Old Lady with Chronic Renal Disease and Intractable Ulcers: A Case Report

        Cases archive
          




        my personal edition > dialysis > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        High-Intensity Dialysis for Acute Kidney Injury Equal to Low-Intensity Dialysis in Treating Intensive Care Patients: Presented at Renal Week 2009

        By Kristina Rebelo

        SAN DIEGO -- November 3, 2009 -- Treatment with higher-intensity continuous renal replacement therapy (CRRT) did not reduce mortality for patients in the intensive care unit (ICU) with acute kidney injury (AKI), according to trial results released here at the American Society of Nephrology (ASN) Renal Week 2009. In fact, higher-intensity CRRT showed no better efficacy than lower-intensity CRRT.

        CRRT is a traditional mode of renal replacement therapy for haemodynamically unstable, fluid-overloaded patients, and also patients with sepsis and septic shock, in the management of acute renal failure, especially in the ICU setting. The optimum intensity of CRRT, however, remains unclear. This multicentre, randomised trial compared the effect of 2 levels of intensity of CRRT on the 90-day mortality in this patient population.

        "Findings from previous smaller studies suggested that higher intensity CRRT saved lives," explained lead investigator Alan Cass, MBBS, PhD, The George Institute's Renal and Metabolic Division and Poche Indigenous Health Centre, University of Sydney, Sydney, Australia, speaking here at a late-breaking abstract session on October 30. Dr. Cass and colleagues randomly assigned critically ill patients with AKI (n = 1,508) to CRRT; the primary outcome measure was death at 90 days after randomisation.

        The patients were assigned to CRRT as postdilution continuous venovenous haemodiafiltration (CVVHDF), with an effluent flow rate of 40 mL/kg/hour for the higher-intensity group (n = 747) and 25 mL/kg/hour for the lower-intensity group (n = 761).

        The study reported results for 721 subjects from the higher-intensity group and 744 subjects from the lower-intensity group. Both groups had similar baseline characteristics and received the CVVHDF treatment for 5.9 and 6.3 days respectively (P = .35).

        There were 322 (44.7%) fatal outcomes in the higher-intensity group and 332 (44.7%) deaths in the lower-intensity group at 90 days post randomisation (odds ratio [OR] 1.00; 95% confidence interval [CI], 0.81-1.23; P = .99).

        No difference in significance was found between the 2 groups for all secondary and tertiary outcomes.

        At 90 days, 6.8% of survivors in the higher-intensity group and 4.4% of survivors in the lower-intensity group were still receiving renal replacement therapy (OR 1.59; 95% CI, 0.86-2.93; P = .14). Hypophosphataemia, however, was more common in the higher-intensity group (54% vs 65%, P < .001).

        "This study, while not consistent with the smaller studies, is consistent with the findings of another recent large trial," Dr. Cass concluded. "It found no benefit with the higher-intensity dialysis over standard, lower dialysis treatment. There was no benefit seen in terms of reduction in deaths or length of time in the hospital, nor was there any difference in the need for ongoing and costly dialysis support."

        [Presentation title: Intensity of Renal Replacement Therapy in Critically Ill Patients: The Randomized Evaluation of Normal Versus Augmented Level Renal Replacement Therapy (RENAL) Study. Abstract LB-006]





        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send